The two blockbusters Novo Nordisk medicines are among 15 additional drugs whose prices Medicare will be allowed to negotiate with drugmakers.

President Donald Trump didn't wait long in his second term to begin shaking things up in Washington, D.C. In less than two ...

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will be subject to the next round of Medicare price negotiations, the Biden ...

The Inflation Reduction Act (IRA) of 2022 brought substantial modifications to the Medicare program, which are still reflected in 2025. One of these changes was a new limit for ded ...

A provision about insulin in the Inflation Reduction Act is conflated with a 2022 executive order by former President Joe ...

Under legislation passed in 2022 called the Inflation Reduction Act, Medicare was allowed for the first time to negotiate prices with drug companies on a limited number of medications.

The Inflation Reduction Act of 2022 has triggered a raft of changes to Medicare Part D plans and Medicare Advantage plans that affect prescription drug coverage in 2025. Here’s what to know.

Biden-era policies rescinded by Donald Trump could signal a significant shake-up in Medicare and Medicaid drug price reforms.

Diabetes and weight loss drugs Ozempic and Wegovy have been added to the list of medications selected for Medicare price negotiations, federal health officials announced Friday. The negotiations for ...

Among the first 10 drugs selected for price negotiations under the 2022 Inflation Reduction Act, cardiometabolic medications ...